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Abstract
Fibrotic interstitial lung diseases (ILDs) are often challenging to diagnose and classify, but an accurate diagnosis has
significant implications for both treatment and prognosis. A subset of patients with fibrotic ILD experience
progressive deterioration in lung function, physical performance, and quality of life. Several risk factors for ILD
progression have been reported, such as male sex, older age, lower baseline pulmonary function, and a radiological
or pathological pattern of usual interstitial pneumonia. Morphological similarities, common underlying
pathobiologic mechanisms, and the consistently progressive worsening of these patients support the concept of a
progressive fibrosing (PF)-ILD phenotype that can be applied to a variety of ILD subtypes. The conventional
approach has been to use antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) and
immunosuppressive medications in patients with other fibrotic ILD subtypes; however, recent clinical trials have
suggested a favourable treatment response to antifibrotic therapy in a wider variety of fibrotic ILDs. This review
summarizes the literature on the evaluation and management of patients with PF-ILD, and discusses questions
relevant to applying recent clinicial trial findings to real-world practice.
Keywords: Interstitial lung disease, Pulmonary fibrosis, Progression, Outcomes, Disease classification, Pulmonary
function tests
Introduction
Interstitial lung disease (ILD) is a heterogeneous group
of diseases characterized by inflammation and fibrosis of
the lung parenchyma [1]. An important subset of pa-
tients with fibrotic ILD experience a decline in lung
function with progressive symptoms, poor response to
treatment, and reduced quality of life. Idiopathic pul-
monary fibrosis (IPF) is the most common, severe, and
progressive subtype of idiopathic interstitial pneumonia
[2]; however, other ILD subtypes also have a progressive
fibrosing phenotype. These include connective tissue
disease-associated ILD (CTD-ILD) [3–5], fibrotic hyper-
sensitivity pneumonitis (HP), unclassifiable ILD, idio-
pathic non-specific interstitial pneumonia (NSIP), and
rarely sarcoidosis, organizing pneumonia, and ILD asso-
ciated with occupational exposures.
The current classification of ILD focuses on identifying
the underlying etiology since this frequently impacts both
management decisions and prognostication [1, 6–9]. The
distinction between IPF and non-IPF ILDs is particularly
important given the worse prognosis in IPF compared to
other fibrosing ILDs [9], and the different approaches to
pharmacotherapy. IPF is primarily a fibrotic ILD, while
fibrosis in non-IPF ILDs is often preceded or associated
with inflammation. These inflammatory pathways can lead
to activation of fibroblasts and their differentiation into
myofibroblasts, which produce extracellular matrix that
perpetuates remodelling of healthy lung tissue to pulmon-
ary fibrosis [10]. Despite important differences, distinct
ILD subtypes often have overlapping morphological
features and common pathological mechanisms, leading
to the concept of a progressive fibrosing phenotype that
can be applied to a variety of fibrotic ILDs [1]. Recent evi-
dence has supported this concept by suggesting some
shared biological mechanisms and greater overlap in treat-
ment options compared to historical approaches [11–15].
In this review, we summarize the current literature on
the disease behaviour, progression of fibrosing ILD other
than IPF, and approaches to management of patients
with fibrosing ILD and a progressive phenotype. We
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discuss the clinical utility of ILD classification according
to disease behavior, potential definitions of progressive
fibrosing ILD (PF-ILD), and challenges for clinical deci-
sion making in the context of emerging treatment possi-
bilities in patients with PF-ILD.
Definition of PF-ILD
Patients with PF-ILD typically have self-perpetuating fi-
brosis characterized by worsening lung function, dyspnea,
physical performance, and quality of life, as well as a poor
response to therapy and early mortality [16]. Approxi-
mately 20–30% of patients with ILD are estimated to have
PF-ILD [3–5]; however, there is no standardized definition
of PF-ILD that clinicians and researchers have agreed
upon. Several criteria have been used to define progres-
sion in patients with IPF, with most of these based on an
absolute or relative decline in forced vital capacity (FVC)
and diffusing capacity of the lung for carbon monoxide
(DLCO) of ≥5–10% or ≥ 10–15% respectively, a decline in
6-min walk distance (6MWD) > 50m, or worsening dys-
pnea and quality of life scores [8, 17–20]. In patients with
systemic sclerosis (SSc)-associated ILD (SSc-ILD), an
absolute 1-year decline in FVC ≥ 10% or 5–9% plus a de-
cline in DLCO ≥15% are strong predictors of mortality
[21]. In RA-ILD, an absolute FVC decline of ≥10% has
been used as evidence of progression based on the in-
creased mortality in patients meeting this threshold [22].
Despite these associations in large cohort studies, FVC
and DLCO trajectories can be unpredictable and are less
reliable among individual patients given important intra-
and interpatient variability [4]. As a result, physicians
typically use a combination of patient-reported symp-
toms, trends in pulmonary function tests, and the evolu-
tion of fibrosis on imaging (Fig. 1) to decide if there is
clinically relevant ILD progression. Recently, several
clinical trials have included patients with a progressive
fibrosing phenotype, with the eligibility criteria for these
studies helping to further guide a standardized definition
of PF-ILD (Table 1) [14, 15, 25].
Risk factors for progression
Retrospective studies have identified risk factors that
increase the likelihood of progression and mortality in PF-
ILD including male sex, older age, lower FVC and DLCO
at baseline, and certain morphological features [3, 6, 9,
21]. Specifically, a radiological and/or histological pattern
of usual intersitial pneumonia (UIP) has been associated
with increased mortality with poor prognosis also seen in
patients with specific radiological features of UIP such as
honeycombing and traction bronchiectasis [26–28]. The
prognostic significance of a UIP pattern is seen across ILD
subtypes, indicating that morphological pattern may be
more prognostically important compared to the specific
etiology of the disease [9, 29, 30].
Fig. 1 Computed tomography imaging of the chest in a patient with progressive unclassifiable interstitial lung disease. Serial apical (a, c, e) and
basal (b, d, f) axial images at baseline (a, b); at 36 months (c, d); and at 42 months (e, f). Images show upper lobe predominant pulmonary
fibrosis with progressive reticulation, traction bronchiectasis, and honeycombing
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An acute exacerbation is the most extreme type of
ILD progression, characterized by a sudden and usually
severe respiratory deterioration with new bilateral opaci-
ties on high-resolution computed tomography (HRCT)
[31]. Risk factors for acute exacerbations in patients with
IPF include severe dyspnea and low quality of life, higher
body mass index, poor oxygenation, and low baseline
FVC and DLCO. Patients with a recent relative decline
in FVC ≥10% or DLCO ≥15% (hence PF-ILD by some
definitions) are also more likely to experience an acute
exacerbation [32–34]. Collectively, these findings suggest
that patients with PF-ILD are at high risk for acute exac-
erbations. Recent studies have demonstrated the promise
of specific blood biomarkers in predicting the risk of
progression, acute exacerbations and mortality in pa-
tients with IPF and other PF-ILD, but additional pro-
spective studies are needed to validate these findings and
confirm their clinical utility [35, 36].
Similar to progression, mortality is challenging to pre-
dict for individual patients, in part related to the unpre-
dictable occurrence of acute exacerbations and the high
mortality from these events. The prognosis for patients
with progressive ILD is worse than for stable and re-
versible ILD, although there is substantial variability
across ILD subtypes even in patients with recent pro-
gression [37].
Most notably, patients with CTD-ILD and fibrotic HP
appear to have a better prognosis than patients with IPF
[9]. Additional data are needed to test whether this as-
sumption of a worse prognosis in IPF remains valid
when comparing to non-IPF patients who also have a
progressive fibrotic phenotype.
Management
Non-pharmacologic treatment
The majority of non-pharmacological management strat-
egies apply to all patients with fibrotic ILD, regardless of
progression or the underlying etiology. Smoking cessa-
tion, antigen avoidance, protection from occupational
exposures, and cessation of medications that can poten-
tially cause ILD are all important. Pneumococcal vaccin-
ation and annual influenza vaccination are also
appropriate in almost all patients with fibrotic ILD. With
frequent loss of physical function and muscle mass in
patients with severe and progressive ILD [38], pulmon-
ary rehabilitation potentially relieves symptoms and
improves exercise capacity [39]. Similarly, selected pa-
tients can benefit from long-term oxygen therapy [40].
Comorbidities and overall frailty can further reduce
quality of life and survival, and patients are consequently
likely to benefit from screening and management of im-
portant comorbidities [41, 42]. Early evaluation for lung
Table 1 Disease severity and definition of progression used in eligibility criteria for selected recently completed and ongoing clinical
trials evaluating PF-ILD
Clinical trial Disease severity Minimum definition of progression
Pulmonary
function
HRCT Time
frame
Pulmonary function Symptoms HRCT
Pirfenidone in unclassifiable ILD
[15]
FVC≥ 45%
DLCO ≥30%
6MWD≥
150m
Fibrosis affecting > 10% of
lung volume
6
months
FVC > 5% decline
(absolute)
Worsening
symptoms
Pirfenidone in progressive non-IPF
ILD (RELIEF) [23]
FVC 40–90%
DLCO 25–
75%
6MWD≥
150m
12
monthsa
FVC≥ 5% decline
(absolute)
Nintedanib in non-IPF PF-ILD
(INBUILD) [14]
FVC≥ 45%
DLCO 30–
80%
Fibrosis affecting > 10% of
lung volume
24
months
FVC≥ 10% decline
(relative)
At least two of:
FVC 5–10% decline
(relative)
Worsening
symptoms
Increasing extent
of fibrosis
Pirfenidone in Patients With RA-
ILD (TRAIL1) [24]
FVC≥ 40%
DLCO ≥30%
Fibrosis affecting > 10% of
lung volume
12
months
FVC≥ 10% decline
(relative)
or
FVC 5–10% decline
(relative) and
DLCO ≥15% decline
(relative)
Abbreviations: DLCO diffusing capacity of the lungs for carbon monoxide, FVC forced vital capacity, HRCT high-resolution computed tomography, ILD interstitial
lung disease, IPF idiopathic pulmonary fibrosis, PF-ILD progressive fibrosing ILD, RA rheumatoid arthritis, 6MWD 6-min walk distance
a≥3 pulmonary function tests within 6–24 months, extrapolated to 12 months
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transplant should be considered for patients with PF-
ILD who are potentially eligible, while symptom-based
management approaches including pallative care should
take priority in patients with severe ILD who are not
candidates for lung transplantation [43].
Pharmacologic treatment
Patients with PF-ILD have generally been treated with
either antifibrotic therapy for IPF or immunosuppressive
therapy for non-IPF ILD. The distinction between IPF
and non-IPF ILD is particularly important because im-
munosuppressive therapy is harmful for patients with
IPF [8], but potentially beneficial for patients with non-
IPF ILD [44, 45]. For this reason, increasing diagnostic
certainty within a multidisciplinary team discussion can
help clinicians make more informed treatment recom-
mendations, and this process can also inform manage-
ment even in patients who are left without a confident
diagnosis [46, 47].
Antifibrotic therapy
Pirfenidone and nintedanib are antifibrotic medications
indicated for the treatment of IPF based on high-quality
randomized placebo-controlled trials [18, 19, 48, 49].
Both medications attenuate migration, differentiation,
and activation of fibroblasts, which are key cells in the
development and progression of pulmonary fibrosis [50].
Preclinical studies suggest an antifibrotic effect in pulmon-
ary fibrosis caused by a variety of different triggers. Both
agents also have anti-inflammatory properties [51, 52].
The clinical trials that led to the approval of nintedanib
and pirfenidone in IPF demonstrated approximately 50%
reduction in the rate of FVC decline in the treated group
compared to placebo, with potential reduction in the risk
of exacerbation and death [18, 19, 49]. Subgroup analyses
from the pirfenidone and nintedanib clinical trials showed
consistent treatment effects regardless of demographics
and disease severity [53, 54]; and post-hoc analyses from
nintedanib trials have further suggested potential efficacy
in a broader population of patients with a multidisciplin-
ary diagnosis of IPF who did not meet IPF diagnostic
criteria from recent clinical practice guidelines [55].
The SENSCIS trial was the first phase III trial to inves-
tigate the efficacy and safety of nintedanib in patients
with a non-IPF ILD [56], and based on this trial the U.S.
Food and Drug Administration recently approved ninte-
danib for the treatment of SSc-ILD. Patients within 7
years of their first non-Raynaud SSc manifestation with
at least 10% fibrosis on HRCT were included in the
study. A stable background therapy with mycophenolate
mofetil (MMF) was permitted, whereas patients with se-
vere pulmonary hypertension or digital ulcers were ex-
cluded. Analysis of the primary outcome showed
approximately 50% reduction in the rate of FVC decline
in the treated group compared to placebo, but patients
had overall less rapid progression compared to the IPF
clinical trial populations [56]. There was no observed
impact of treatment on Rodnan skin score or health-
related quality of life. Tolerability of nintedanib was ac-
ceptable with a similar adverse effect profile compared
to IPF patients. Diarrhea was the most frequent adverse
effect, experienced by 76% of patients in the nintedanib
and 32% of patients in the placebo group. The subgroup
of patients receiving background MMF had less relative
benefit from nintedanib compared to placebo (mean
between-group difference 26mL/year in patients on
MMF versus 55 mL/year in patient without MMF).
An open-label phase 2 study showed acceptable ad-
verse events profile of pirfenidone in patients with SSc-
ILD [57]. Tolerability of pirfenidone was similar to pa-
tients with IPF, with a slightly better tolerability when
pirfenidone was titrated over 4 weeks instead of 2 weeks.
In addition to SSc-ILD, recently published clinical
studies have investigated the effect of nintedanib and
pirfenidone in patients with unclassifiable and other
non-IPF PF-ILDs, with similar study designs compared
to the previous IPF trials (Table 2). The INBUILD trial
showed that annual FVC decline in PF-ILD patients re-
ceiving nintedanib was reduced by 57% (107 ml) com-
pared to placebo, with more than 60% reduction in FVC
decline (128 ml) in patients who had a radiologic UIP-
like pattern [14]. Patients in the INBUILD study were
not permitted use of immunosuppressive medications,
possibly suggesting a study population with less abun-
dant inflammatory features. Several studies of pirfeni-
done have enrolled patients with a variety of non-IPF
PF-ILD subtypes who have worsened despite therapy,
including a study in unclassifiable ILD [15], and another
study published only in abstract form that included
patients with CTD-ILD, fibrotic idiopathic NSIP, fibrotic
HP, and ILD associated with asbestosis [23]. In a recent
phase 2 study evaluating pirfenidone in unclassifiable
ILD, the safety profile of pirfenidone was reassuring with
promising, but inconsistent efficacy signals that
depended on both the endpoint and the method of
statistical analysis. Specifically, FVC measured by daily
home spirometry was chosen as the primary endpoint
in this trial; however, these measurements were highly
variable and prohibited performance of the planned
statistical analysis. More reassuringly, results from
spirometry performed at the study sites suggested a
slower rate of FVC decline in patients on pirfenidone
compared to placebo [15]. There are several ongoing
studies that will further clarify the roles for ninteda-
nib and pirfenidone in PF-ILD (Table 3). Regulatory
bodies will soon make decisions on whether antifibro-
tic medications will receive indications for use in
non-IPF ILDs.
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Immunosuppressive therapies
Immunosuppressive medications are not appropriate in
the chronic management of IPF given the increased risk
of mortality and other adverse consequences, without
any clear benefit [8]. Based on these findings, immuno-
suppressive medications are used with great caution in
patients with an IPF-like phenotype. Conversely, these
medications are generally considered appropriate in
Table 2 Major randomized controlled trials investigating antifibrotic or immunosuppressive treatments in patients with non-IPF ILD
Study Patient
population
(sample size)
Treatmenta 1o endpoint Selected 2o endpoints
Antifibrotic medication
SENSCIS
(Phase 3) [56]
NCT02597933
SSc-ILD (576) Nintedanib Nintedanib reduced the rate of FVC
decline over 52 weeks (mean between-
group difference 41 mL; 95%CI 2.9-79 mL,
p = 0.04), with smaller absolute benefit
from nintedanib compared to IPF clinical
trials.
No difference in mRSS and QOL.
INBUILD
(Phase 3) [14]
NCT02999178
PF-ILD (663):
Fibrotic HP,
CTD-ILD, iNSIP,
unclassifiable
ILD
Nintedanib Nintedanib reduced the rate of FVC
decline over 52 weeks (mean between-
group difference 107mL; 95%CI 65-149
mL, p < 0.001), with similar absolute benefit
from nintedanib compared to IPF clinical
trials.
No difference in QOL and survival.
LOTUSS
(Phase 2/
Open-label)
[57]
NCT01933334
SSc-ILD (63) Pirfenidone
(stable background
therapy with MMF
allowed)
An adverse event occurred in 97% of
patients over 16 weeks. Patients in the 4
week titration group had improved
tolerability compared to patients in the 2
week titration group. Tolerability was
similar among patients on both MMF and
pirfenidone compared to patients on
pirfenidone only.
No difference in FVC, DLCO, patient-
reported outcomes or mRSS between the
titration groups.
RELIEF (Phase
2) [23]
DRKS00009822
PF-ILD (127):
CTD-ILD, fibrotic
iNSIP, fibrotic
HP, asbestosis
Pirfenidone (added to
conventional therapy)
Pirfenidone reduced the rate of FVC
decline over 48 weeks when statistical
analyses used imputed data.
No difference in DLCO, 6MWD, QOL, and
safety profile.
Pirfenidone
in
unclassifiable
ILD (Phase 2)
[15]
NCT03099187
Unclassifiable
PF-ILD (253)
Pirfenidone (stable
background therapy
with MMF allowed)
The prespecified analysis could not be
performed due to high variability for
individual daily home spirometry readings.
Pirfenidone reduced the rate of FVC
decline over 24 weeks using site
spirometry (mean between-group differ-
ence 95.3 mL, 95%CI 36-155mL, p = 0.002).
No differences in DLCO, 6MWD, and
safety.
Immunosuppressive medication
SLS (Phase 3)
[45]
NCT00004563
SSc-ILD (158) CYC p.o. CYC reduced the rate of FVC decline over
52 weeks (mean between-group difference
2.53, 95%CI 0.28–4.79%, p < 0.03) after ad-
justment for baseline FVC.
More adverse events in the CYC group.
SLS II (Phase
3) [58]
NCT00883129
SSc-ILD (126) MMF for 2 years versus
CYC p.o. for 1 year
followed by placebo
for 1 year
No between-group difference in FVC over
24 months with a greater proportion of pa-
tients withdrawing from CYC than from
MMF.
No between-group difference in mRSS,
change in HRCT lung fibrosis scores, or
dyspnea score.
FAST [59] SSc-ILD (45) 6 months of CYC i.v.
and prednisone
followed by 6 months
of AZA versus placebo
No between-group difference in FVC over
52 weeks in this small, potentially under-
powered study.
No between-group differences in HRCT fi-
brosis and dyspnea scores.
FOCUSSED
(Phase 3)
NCT02453256
[presented in
abstract form]
SSc (210)
including SSc-
ILD (132)
Tocilizumab No statistically significant difference in
mRSS over 48 weeks (adjusted mean
between-group difference − 1.73, 95%CI
−3.78-0.32, p = 0.098).
Tocilizumab reduced the rate of FVC
decline over 48 weeks on post-hoc analysis
in the subgroup of patients with SSc-ILD
(mean between-group difference 6.4,
95%CI 3.3–9.4%)
Abbreviations: AZA azathioprine, CI confidence interval, CTD connective tissue disease, CYC cyclophosphamide, DLCO diffusing capacity of the lungs for carbon
monoxide, FVC forced vital capacity, HP hypersensitivity pneumonitis, HRCT high-resolution computed tomography, ILD interstitial lung disease, iNSIP idiopathic
nonspecific interstitial pneumonia, IPF idiopathic pulmonary fibrosis, i.v. intravenous, MMF mycophenolate mofetil, mRSS modified Rodnan skin score, p.o. per os,
QOL quality of life, SSc systemic sclerosis, 6MWD 6-min walk distance
acompared to placebo unless otherwise stated
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many patients with CTD-ILD or fibrotic HP, and in
some patients with unclassifiable ILD (Table 2) [44].
Connective tissue disease-associated ILD Most evi-
dence for the use of immunosuppressive medications in
CTD-ILD is extrapolated from the Scleroderma Lung
Study [45]. This study showed that patients receiving
cyclophosphamide had a slower rate of FVC decline com-
pared to placebo, with a mean absolute difference of 2.5%
between groups after 1 year of therapy. However, concerns
of toxicity, low tolerability, and loss of effect after 18
months led to the Scleroderma Lung Study II which com-
pared 2 years of MMF to 1 year of oral cycphosphamide
[58]. Although MMF and cyclophosphamide had similar
efficacy, MMF had less hematotoxicity and substantially
fewer premature study withdrawals. MMF is consequently
the preferred initial and maintenance immunosuppressive
agent for most patients with SSc-ILD [60]. Besides
cyclophosphamide and MMF, other frequently used medi-
cations in CTD-ILD include azathioprine, methotrexate,
and rituximab.
Tocilizumab is a subcutaneously administered inter-
leukin 6 receptor-α inhibitor that was recently studied in
phase II and III trials in patients with early and progres-
sive SSc. The studies did not meet their primary end-
point, which was the difference in change of the
modified Rodnan skin score between groups [57, 61].
Recent results from exploratory and post-hoc analyses
Table 3 Ongoing randomized controlled trials investigating antifibrotic and immunosuppressive treatments in non-IPF ILD
Study Patient population (sample size) Treatmenta 1o endpoint Selected 2o
endpoints
Expected
completion
date
Antifibrotic medications
SLS III (Phase 2)
NCT03221257
SSc-ILD (150) Pirfenidone (added to
MMF)
Change in FVC over 18
months
Change in DLCO,
mRSS, QOL,
Dyspnea
December
2021
Pirfenidone in SSc-
ILD (Phase 3)
NCT03856853
SSc-ILD (144) Pirfenidone Change in FVC over 52 weeks February
2021
TRAIL1 (Phase 2)
NCT02808871
RA-ILD (270) Pirfenidone Incidence of composite
endpoint of FVC decline
≥10% or death over 52 weeks
Frequency of
progressive fibrosis
(FVC decline≥ 10%,
or 5–10% and DLCO
decline≥ 15%)
November
2021
PirFS
NCT03260556
PF-sarcoidosis (60) Pirfenidone Time to clinical worsening
over 24 months
Change in FVC and
composite
physiologic index
December
2019
Pirfenidone Fibrotic
HP NCT02958917
Fibrotic HP (40) Pirfenidone Change in FVC over 52 weeks Progression-free
survivalb
December
2019
Pirfenidone in DM-
ILD (Phase 3)
NCT03857854
DM-ILD (152) Pirfenidone Change in FVC over 52 weeks February
2021
Immunosuppressive medications
RECITAL (Phase 2–
3) NCT01862926
CTD-ILD (116) Rituximab versus CYC Change in FVC over 48 weeks Adverse events,
change in DLCO
and QOL
November
2020
Bortezomib and
MMF in SSc-ILD
(Phase 2)
NCT02370693
SSc-ILD (30) Bortezomib (added to
standard of care
immunosuppression)
Safety over 24 weeks Change in FVC,
mRSS, QOL
June 2020
EvER-ILD (Phase 3)
NCT02990286
Idiopathic or CTD-associated NSIP
(non-responders to first-line im-
munosuppression) (122)
Rituximab (added to
standard of care
immunosuppression)
Change in FVC over 6
months
Change in 6MWD,
DLCO, dyspnea,
cough
June 2020
ATtackMy-ILD
(Phase 2)
NCT03215927
Myositis associated ILD (20) Abatacept (added to
standard of care
immunosuppression)
Change in FVC over 24 weeks Progression-free
survivalc and
change in dyspnea
December
2020
Abbreviations: CTD connective tissue disease, CYC cyclophosphamide, DLCO diffusing capacity of the lungs for carbon monoxide, DM dermatomyositis, FVC forced
vital capacity, HP hypersensitivity pneumonitis, HRCT high-resolution computed tomography, ILD interstitial lung disease, MMF mycophenolate mofetil, mRSS
modified Rodnan skin score, NSIP idiopathic nonspecific interstitial pneumonia, QOL quality of life; SSc, systemic sclerosis, 6MWD 6-min walk distance
acompared to placebo unless otherwise stated
btime to FVC %-predicted decline ≥5%, or 6MWD decline ≥50 m, or progression of fibrosis on HRCT, or acute exacerbation
ctime to FVC%-predicted decline ≥10%, or ≥ 5% and DLCO %-predicted decline ≥15%, or death or lung transplantation
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revealed that fewer SSc-ILD patients in the tocilizumab
group had a decline in FVC at 48 weeks, with quantita-
tive lung fibrosis scores also supporting potential benefit
from tocilizumab in this subgroup.
Fibrotic hypersensitivity pneumonitis Immunosup-
pressive medications are frequently used in patients with
fibrotic HP despite the absence of prospective controlled
trials. In patients with non-fibrotic HP, short courses of
prednisone combined with exposure elimination may be
sufficient to halt and even reverse the disease process. Man-
agement is more challenging in fibrotic HP, with many pa-
tients having a progressive fibrotic phenotype even with
exposure elimination. Based on retrospective comparisons
in patients with fibrotic HP, both MMF and azathioprine
are well-tolerated, potentially reduce the need for prednis-
one, and may improve the trajectory of DLCO decline [44].
Despite the limited data, MMF and azathioprine are typic-
ally considered first-line options for patients with fibrotic
HP who have had or are at risk of ongoing progression.
Unclassifiable ILD Approximately 12% of patients with
ILD cannot be classified after a diagnostic workup, and
management is particularly challenging in this patient
population [62]. Unclassifiable ILD is a diverse collection
of patients who frequently have features resembling
CTD-ILD or fibrotic HP. The concept of a working diag-
nosis has been suggested as a useful approach in decid-
ing upon the most appropriate management of these
patients [46]. Depending on the relative likelihoods of
different diagnoses in a patient with unclassifiable ILD,
either antifibrotic or immunosuppressive therapy may be
warranted. The use of immunosuppressive therapies in
this situation is based on very limited retrospective data
suggesting potential benefit from cyclophosphamide in
the subgroup of unclassifiable ILD patients who have
autoimmune features [63, 64].
Additional clinical trials are ongoing that might pro-
vide further evidence on the efficacy and safety of im-
munosuppressive therapies in patients with non-IPF
ILDs (Table 3).
Discussion
The disease behaviour of various ILD subtypes has been
studied in many observational cohorts and clinical trials,
with many of these studies focusing on patients with a
progressive fibrotic phenotype. The eligibility criteria of
these studies have provided a starting point for the def-
inition of PF-ILD [14, 15, 23, 24], with the clinical utility
of this concept supported by the therapeutic benefits
observed in some of these clinical trials [14, 15]. Despite
these significant advances, there are many uncertainties
that still remain in the classification and management of
PF-ILD.
Is the concept of PF-ILD clinically useful?
Establishing a confident ILD diagnosis is often challen-
ging, with considerable heterogeneity in diagnoses
assigned by different experienced multidisciplinary
teams [47], and approximately 12% of patients remaining
unclassifiable after a thorough evaluation including a
surgical lung biopsy [62]. Although diagnostic certainty
is often low in ILD, it is typically still feasible to
characterize disease behaviour using symptoms or rou-
tine investigations such as pulmonary function tests and
chest imaging.
There is therefore appeal to simply classifying patients
with ILD based on previous or anticipated disease be-
haviour rather than needing to establish a confident
diagnosis; however, there are also important disadvan-
tages of this approach. First, this approach could detract
from a thorough assessment for an underlying etiology,
with the danger that crucial management steps such as
antigen avoidance might be neglected, or that specific
pharmacotherapy options may not be considered. Sec-
ond, creation of such a large and heterogeneous cohort
would complicate development and testing of targeted
therapies that apply to specific subgroups. Finally, trans-
lation of clinical trial findings from a heterogenuous co-
hort to individual patients might be challenging, with
limited ability to understand whether clinical trial results
are being driven by a specific subset of patients.
Despite these concerns, recent clinical trials support
the clinical utility of PF-ILD by demonstrating potential
treatment implications of this designation [14, 15]. It is
therefore likely that the concept of PF-ILD will become
further incorporated into clinical practice; however, with
the important caveat that disease behaviour should be
complementary to the current approach to ILD classifi-
cation, rather than replacing it.
How should PF-ILD be defined?
There are no established diagnostic criteria available to
determine disease progression or a definition of PF-ILD.
Clinical trials have consistently defined PF-ILD based on
worsening symptoms, pulmonary function, or imaging;
however the specific combination of features and thresh-
olds vary across studies (Table 1).
Decline in pulmonary function is a key criterion for
PF-ILD in all studies, with a relative decline in FVC
≥10% being a common threshold for progression
when used in isolation. Smaller changes in FVC (e.g.
relative decline of 5–10%) are less specific [4, 65],
and are typically complemented by worsening symp-
toms or imaging findings, which are often defined
qualitatively. Most recent studies have not included
DLCO in their definition of PF-ILD; however, previ-
ous studies and working group statements have pro-
posed ≥15% decline in DLCO is clinically meaningful,
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with smaller changes often used in combination with
other markers of ILD progression [20, 21].
Criteria for progression that are used in recent
studies may not translate directly into a clinical set-
ting. Notably, imaging studies are not feasible at all
follow-up visits, and thus radiological progression will
likely be a relatively infrequent criterion of disease
progression in clinical practice. In addition, experi-
enced clinicians frequently integrate these markers of
progression in a more complex manner than what can
feasibly be replicated in a clinical trial that prioritizes
standardization. Finally, clinicians have many other markers
of ILD progression to consider on an individual basis, in-
cluding exercise capacity, oxygenation, and respiratory
hospitalization. It is therefore likely that there will be some
differences in how PF-ILD has been defined in clinical trials
compared to how clinicians will define this subgroup in a
real-world setting.
How should clinicians choose between antifibrotic or
immunosuppressive therapy in patients with non-IPF PF-
ILD?
Antifibrotic and immunosuppressive medications are
both currently off-label for patients with non-IPF PF-
ILD; however, recent data have generated interest in
using these medications in some of these patients pend-
ing the necessary regulatory approvals.
In the future, potential management options for pa-
tients with PF-ILD will likely include no specific
pharmacological treatment, immunosuppressive medica-
tion, antifibrotic medication, or a combination of these
treatments.
The option to forgo initiation of both immunosup-
pressive and antifibrotic therapy will usually apply to
patients with significant comorbidities, those who are
likely to tolerate potential adverse effects poorly, pa-
tients in a palliative setting, and those who decline
pharmacotherapy for other reasons. The choice be-
tween antifibrotic and immunosuppressive medication
in PF-ILD has not been answered by recent clinical trials,
as none of these studies have directly compared these two
options [14, 15]. In the absence of robust head-to-head
data, it will likely be most appropriate to consider antifi-
brotic medication in patients with an IPF-like phenotype,
particularly those with a UIP pattern on chest imaging or
lung biopsy, as well as patients for whom immunosup-
pression might be associated with greater potential ad-
verse effects. Using immunsuppressive therapy as a first-
line option is likely to be most beneficial in patients with a
more inflammatory phenotype, and particularly those with
an organising pneumonia pattern on chest imaging and
other features of active autoimmunity [63, 64]. There is a
substantial “grey zone” of patients with fibrotic ILD who
fall between these two extremes. Decisions in these
patients will be more challenging, and should gener-
ally be supported by a multidisciplinary discussion as
well as close communication with rheumatologists in
patients with features of a CTD. In this situation,
some clinicans use a brief trial (e.g., 1–2 months) of
prednisone to identify potential candidates for long-
term immunosuppression, prioritizing ongoing im-
munosuppression in patients who respond favourably
to this shorter trial. The pragmatic assumption that
short-term response to prednisone translates into
long-term benefit of immunsuppressive medication
needs to be established in controlled trials, and there
is also the important downside that this approach is
very likely harmful in patients with an underlying
biology similar to IPF [8]. This approach should thus
be used with caution. Lastly, the combination of anti-
fibrotic and immunosuppressive medications is a po-
tential option given that both therapies are targeting
different biological pathways involved in the biology
of non-IPF PF-ILD. Recent studies have shown that
the combination of pirfenidone and MMF is safe in
patients with unclassifiable ILD and similarly for nin-
tedanib and MMF in SSc-ILD [15, 56].
Many questions remain to be answered in future
studies of PF-ILD: Which antifibrotic and immuno-
suppressive therapies can be combined safely? What
is the incremental benefit of these medications when
added to an established background therapy? Should
antifibrotics and immunosuppressants be combined
upfront or sequentially only in the context of on-
going disease progression? How should response to
these treatments be assessed? And how should the
additional therapeutic burden be managed, particu-
larly, in polymorbid and frail patients? Additional
clinical trials are forthcoming that will provide fur-
ther insight into these questions, as well as antici-
pated post-hoc analyses from recently published
studies.
Conclusion
The term PF-ILD identifies a subgroup of patients
with ILD who often have a poor prognosis, with re-
cent clinical trials suggesting potential benefit from
antifibrotic medication in this population. These tri-
als support the utility of subclassifying patients with
various fibrotic ILD subtypes based on their antici-
pated disease behaviour; however, it is critical to re-
member that this approach is complementary to
establishing a confident clinical diagnosis that also
carries important management and prognostic impli-
cations. Although recent advances have suggested
exciting new options for patients with fibrotic ILD,
many questions remain and collaborative efforts are
needed to address these issues.
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